Du Jie, Wu Jianjun, Zhang Youqi, Liu Qi, Luo Xing, Huang Xingtao, Wang Xuedong, Yang Fan, Hou JingBo
Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Key Laboratory of Myocardial Ischemia, Ministry of Education, Harbin, Heilongjiang, China (mainland).
Med Sci Monit. 2024 Jan 26;30:e942733. doi: 10.12659/MSM.942733.
BACKGROUND C1q/tumor necrosis factor-related protein 13 (CTRP13) preserves endothelial function and possesses anti-oxidation activity. However, its effects on ferroptosis of human umbilical vein endothelial cells (HUVECs) remain unclear. We investigated the effects of CTRP13 on HUVEC ferroptosis induced by oxidized low-density lipoprotein (ox-LDL) and explored the underlying mechanisms of CTRP13 against ferroptosis via the AMPK/KLF4 pathway. MATERIAL AND METHODS Cell Counting Kit-8 assay was used to evaluate cell viability. Lactate dehydrogenase activity and malondialdehyde content analysis were performed to evaluate the cell membrane integrity and lipid peroxidation. Mito-Tracker, JC-1, and 2',7'-dichlorofluorescein di-acetate were used to evaluate the biological activity of mitochondria, mitochondrial membrane potential, and reactive oxygen species (ROS) in endothelial cells. The ferroptosis indicator expressions, recombinant solute carrier family 7, member 11, glutathione peroxidase 4 (GPX4), and acyl-CoA synthetase long-chain family member 4 were examined using real-time reverse transcription-polymerase chain reaction and Western blot. Immunofluorescence staining detected GPX4 location in endothelial cells. RESULTS The results demonstrate that CTRP13 (450 ng/mL) prevented HUVEC ferroptosis by inhibiting ROS overproduction and mitochondrial dysfunction, and CTRP13 accelerated antioxidant enzyme expression levels, such as heme oxygenase 1, superoxide dismutase 1, and superoxide dismutase 2, compared with the ox-LDL (100 µg/mL) group for 48 h. Additionally, CTRP13 treatment increased p-AMPK/AMPK expression by 47.65% (P<0.05) while decreasing Krüppel-like factor 4 expression by 37.43% (P<0.05) in ox-LDL-induced HUVECs and elucidated the protective effect on endothelial dysfunction from ferroptosis. CONCLUSIONS These findings provide new insights for understanding the effects and mechanism of CTRP13 on preventing endothelial cell ferroptosis.
背景 C1q/肿瘤坏死因子相关蛋白13(CTRP13)可维持内皮功能并具有抗氧化活性。然而,其对人脐静脉内皮细胞(HUVECs)铁死亡的影响仍不清楚。我们研究了CTRP13对氧化型低密度脂蛋白(ox-LDL)诱导的HUVECs铁死亡的影响,并探讨了CTRP13通过AMPK/KLF4途径对抗铁死亡的潜在机制。
材料与方法 使用细胞计数试剂盒-8法评估细胞活力。进行乳酸脱氢酶活性和丙二醛含量分析以评估细胞膜完整性和脂质过氧化。使用线粒体追踪染料、JC-1和2',7'-二氯荧光素二乙酸酯评估内皮细胞中线粒体的生物学活性、线粒体膜电位和活性氧(ROS)。使用实时逆转录-聚合酶链反应和蛋白质免疫印迹法检测铁死亡指标溶质载体家族7成员11、谷胱甘肽过氧化物酶4(GPX4)和酰基辅酶A合成酶长链家族成员4的表达。免疫荧光染色检测GPX4在内皮细胞中的定位。
结果 结果表明,与48小时的ox-LDL(100μg/mL)组相比,CTRP13(450ng/mL)通过抑制ROS过度产生和线粒体功能障碍预防了HUVECs铁死亡,并且CTRP13加速了抗氧化酶的表达水平,如血红素加氧酶1、超氧化物歧化酶1和超氧化物歧化酶2。此外,在ox-LDL诱导的HUVECs中,CTRP13处理使p-AMPK/AMPK表达增加了47.65%(P<0.05),同时使Krüppel样因子4表达降低了37.43%(P<0.05),并阐明了其对铁死亡引起的内皮功能障碍的保护作用。
结论 这些发现为理解CTRP13预防内皮细胞铁死亡的作用和机制提供了新的见解。